Geneses Drug Testing is categorized under Inspection Services in Pleasanton, TX and active since 2013.
Geneses Drug Testing was established in 2013, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Inspection Services business, which does work in the B2B market, and is classified as a Inspection Services, under code number 6215110 by the NAICS.
If you are seeking more information, feel free to contact Jerry Gallegos, Owner at the company’s single location by writing to 1713 East State Highway 97, Pleasanton, Texas TX 78064 or by phoning (830) 569-8443. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Geneses Drug Testing |
Contact Person: | Jerry Gallegos, Owner |
Address: | 1713 East State Highway 97, Pleasanton, Texas 78064 |
Phone Number: | (830) 569-8443 |
Website Address: | genesisdrugtesting.com |
Annual Revenue (USD): | $1.000.000 to $2.499.999 |
Founded: | 2013 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Inspection Services |
SIC Code: | 7389 |
NAICS Code: | 6215110 |
Share This Business: |
Geneses Drug Testing was started in 2013 to provide professional Inspection Services under the SIC code 7389 and NAICS code 6215110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Jerry Gallegos, Owner for inquiries that concern Geneses Drug Testing by calling the company number (830) 569-8443, as your correspondence is most welcome. Additionally, the physical location of the single location of Geneses Drug Testing can be found at the coordinates 28.97845,-98.46706 as well as the street address 1713 East State Highway 97 in Pleasanton, Texas 78064.
For its online presence, you may visit Geneses Drug Testing’s website at genesisdrugtesting.com and engage with its social media outlets through on Twitter and on Facebook.